Clinical Trials
2 trialsNCT04639180 2025-12-30
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Active not recruiting
NCT06124001 2023-11-15
Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma
CNBG-Virogin Biotech (Shanghai) Ltd.
Phase 1/2 Not yet recruiting